바로가기메뉴

본문 바로가기 주메뉴 바로가기

Tuberculosis & Respiratory Diseases

Article Contents

Prev Next
e-Submission

Vol.69 No.4
Citation Share

Moxifloxacin Alleviates Oleic Acid-provoked Neutrophilic Respiratory Burst in the Rat Lung through the Inhibition of Cytosolic Phospholipase A2

Tuberculosis & Respiratory Diseases / Tuberculosis & Respiratory Diseases,
2010, v.69 no.4, pp.256-264

(2010). Moxifloxacin Alleviates Oleic Acid-provoked Neutrophilic Respiratory Burst in the Rat Lung through the Inhibition of Cytosolic Phospholipase A2. Tuberculosis & Respiratory Diseases, 69(4), 256-264.
  • Downloaded
  • Viewed
PDF Download

Abstract

Background: According to the notion of the immunoregulatory functions of moxifloxacin (MFX), the effect of MFX on the neutrophilic respiratory burst in conjunction with the expression of cytosolic phospholipase A2 (cPLA2) was investigated. Methods: The effects and possible mechanisms of MFX on neutrophilic respiratory burst in oleic acid (OA)-induced acutely injured rats lung and OA-stimulated, isolated murine neutrophils were probed, associated with the expression of cytosolic phospholipase A2 in vivo and in vitro. Results: In the OA-induced acutely-injured lungs, neutrophils were accumulated, which was attenuated by MFX. The parameters denoting a neutrophilic respiratory burst, such as nitro blue tetrazolium reaction, cytochrome-c reduction, neutrophil aggregation, H2O2 production in neutrophils revealed increased neutrophilic respiratory burst by OA, and MFX decreased all of these parameters. In addition, the enhanced expression of cPLA2 in the lung and isolated murine neutrophils by OA were decreased by MFX. Conclusion: MFX suppresses the OA-induced neutrophilic respiratory burst by the suppression of cPLA2 in neutrophils.

keywords
Oleic Acid, Neutrophils, Phospholipases A2, Cytosolic, Moxifloxacin, Oleic Acid, Neutrophils, Phospholipases A2, Cytosolic, Moxifloxacin

Reference

1.

1. Ware LB. Advances in the pathogenesis and treatment of the acute respiratory distress syndrome. Clin Pul Med 2003;10:208-18.

2.

2. Kitsiouli E, Nakos G, Lekka ME. Phospholipase A2 subclasses in acute respiratory distress syndrome. Biochim Biophys Acta 2009;1792:941-53.

3.

3. Nakos G, Kitsiouli E, Hatzidaki E, Koulouras V, Touqui L, Lekka ME. Phospholipases A2 and platelet-activating-factor acetylhydrolase in patients with acute respiratory distress syndrome. Crit Care Med 2005;33:772-9.

4.

4. Stommer P, Steinmann U. Phospholipase A2 induced diffuse alveolar damage: effect of indomethacin and dexamethasone upon morphology and plasma-histamine level. Klin Wochenschr 1989;67:171-6.

5.

5. Schaloske RH, Dennis EA. The phospholipase A2 superfamily and its group numbering system. Biochim Biophys Acta 2006;1761:1246-59.

6.

6. Wheeler DS. Phospholipase A2 and acute lung injury:it's just not that simple. Crit Care Med 2005;33:904-5.

7.

7. Pruzanski W, Vadas P. Phospholipase A2: a mediator between proximal and distal effectors of inflammation.Immunol Today 1991;12:143-6.

8.

8. Arbibe L, Vial D, Touqui L. Phospholipase A2 and acute respiratory distress syndrome. Prog Surg 1997;24:79-87.

9.

9. Kramer RM, Sharp JD. Structure, function and regulation of Ca2+-sensitive cytosolic phospholipase A2 (cPLA2). FEBS Lett 1997;410:49-53.

10.

10. Dana R, Malech HL, Levy R. The requirement for phospholipase A2 for activation of the assembled NADPH oxidase in human neutrophils. Biochem J 1994;297:217-23.

11.

11. Lucas KK, Dennis EA. The ABC's of Group IV cytosolic phospholipase A2. Biochim Biophys Acta 2004;1636:213-8.

12.

12. Huang HC, Shieh CC, Yu WL, Cheng KC, Chen CC,Chang ST, et al. Comparing the protective effects of ciprofloxacin,moxifloxacin and levofloxacin in mice with lipopolysaccharide-induced acute lung injuries. Respirology 2008;13:47-52.

13.

13. Wang JP, Raung SL, Huang LJ, Kuo SC. Involvement of cyclic AMP generation in the inhibition of respiratory burst by 2-phenyl-4-quinolone (YT-1) in rat neutrophils.Biochem Pharmacol 1998;56:1505-14.

14.

14. Weiner RE, Sasso DE, Gionfriddo MA, Syrbu SI,Smilowitz HM, Vento J, et al. Early detection of bleomycin-induced lung injury in rat using indium-111-labeled antibody directed against intercellular adhesion molecule-1. J Nucl Med 1998;39:723-8.

15.

15. Goldblum SE, Wu KM, Jay M. Lung myeloperoxidase as a measure of pulmonary leukostasis in rabbits. J Appl Physiol 1985;59:1978-85.

16.

16. Hobson J, Wright J, Churg A. Histochemical evidence for generation of active oxygen species on the apical surface of cigarette-smoke-exposed tracheal explants.Am J Pathol 1991;139:573-80.

17.

17. Haslett C, Guthrie LA, Kopaniak MM, Johnston RB Jr,Henson PM. Modulation of multiple neutrophil functions by preparative methods or trace concentrations of bacterial lipopolysaccharide. Am J Pathol 1985;119:101-10.

18.

18. Botha AJ, Moore FA, Moore EE, Fontes B, Banerjee A,Peterson VM. Postinjury neutrophil priming and activation states: therapeutic challenges. Shock 1995;3:157-66.

19.

19. Dalhoff A, Shalit I. Immunomodulatory effects of quinolones.Lancet Inf Dis 2003;3:359-71.

20.

20. Koksel O, Cinel I, Tamer L, Cinel L, Ozdulger A, Kanik A, et al. N-acetylcysteine inhibits peroxynitrite-mediated damage in oleic acid-induced lung injury. Pulm Pharmacol Ther 2004;17:263-70.

21.

21. Karagiorga G, Nakos G, Galiatsou E, Lekka ME.Biochemical parameters of bronchoalveolar lavage fluid in fat embolism. Intensive Care Med 2006;32:116-23.

22.

22. Julien M, Hoeffel JM, Flick MR. Oleic acid lung injury in sheep. J Appl Physiol 1986;60:433-40.

23.

23. Lee YM, Kim BY, Park YY. Role of the PLA2-activated neutrophilic oxidative stress in oleic acid-induced acute lung injury. Tuberc Respir Dis 2010;68:55-61.

24.

24. Shmelzer Z, Haddad N, Admon E, Pessach I, Leto TL,Eitan-Hazan Z, et al. Unique targeting of cytosolic phospholipase A2 to plasma membranes mediated by the NADPH oxidase in phagocytes. J Cell Biol 2003;162:683-92.

25.

25. Leslie CC. Properties and regulation of cytosolic phospholipase A2. J Biol Chem 1997;272:16709-12.

26.

26. Ghosh M, Tucker DE, Burchett SA, Leslie CC. Properties of the Group IV phospholipase A2 family. Prog Lipid Res 2006;45:487-510.

27.

27. Nagase T, Uozumi N, Ishii S, Kume K, Izumi T, Ouchi Y, et al. Acute lung injury by sepsis and acid aspiration:a key role for cytosolic phospholipase A2. Nat Immunol 2000;1:42-6.

28.

28. Magrioti V, Kokotos G. Phospholipase A2 inhibitors as potential therapeutic agents for the treatment of inflammatory diseases. Expert Opin Ther Pat 2010;20:1-18.

Tuberculosis & Respiratory Diseases

e-Submission OA Policy